Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

New Drug More Effective in Treating Afib

May 2, 2016 10:10 am | by Medical University of Vienna | News | Comments

Vernakalant, a new drug for treating recent-onset atrial fibrillation, has proved to be considerably more effective than Ibutilide, an established drug in this indication.


At the Vatican, Biden Seeks Common Cause with Pope on Cancer

May 2, 2016 9:47 am | by Josh Lederman, Associated Press | News | Comments

Vice President Joe Biden found common cause with Pope Francis on Friday at the Vatican for a global commitment to fund cancer research.


FDA Reconsiders Training Requirements for Painkillers

May 2, 2016 8:41 am | by Matthew Perrone, AP Health Writer | News | Comments

The FDA first proposed its risk-management plan in 2010, before the CDC had formally identified opioid overdoses as a national epidemic.


New Cancer Drugs Could Treat Lethal Resistant Prostate Cancers

May 2, 2016 8:38 am | by Institute of Cancer Research | News | Comments

The research suggests that Hsp90 inhibitors could be effective in prostate cancers that have become resistant to treatment and started spreading round the body.


Scientists Discover Drugs that Could Fight Antibiotic-Resistant Bacteria

May 2, 2016 8:30 am | by Beth Israel Deaconess Medical Center | News | Comments

Investigators have developed a promising method of identifying new antimicrobials that target these organisms. 


How Scientists Use DNA to Track Disease Outbreaks

May 2, 2016 8:28 am | by Emily Toth Martin, University of Michigan, The Conversation | News | Comments

Genetic sequencing allows us to determine how an infection travels – even tracing it across continents – with incredible precision.


First Widely Available Zika Test Ok'd for Emergency Use

May 2, 2016 8:28 am | by The Associated Press | News | Comments

The first commercial test for the Zika virus has been cleared for emergency use in the U.S. and could be available by next week.


EMA Recommends Approval for Biogen, AbbVie's MS Drug

May 1, 2016 11:30 am | News | Comments

The drug is also currently under regulatory review in the United States, Switzerland, Canada and Australia.


Novo Nordisk Says US Launch 'Encouraging' as Profit Drops

April 29, 2016 10:30 am | News | Comments

The world's largest maker of diabetes treatments, Novo Nordisk, said on Friday that the US launch of ultra-long acting insulin Tresiba had been "encouraging" as it reported a drop in first quarter profit.


New Non-Invasive Brain Stimulation Technique for Pain Management

April 29, 2016 10:27 am | by European Journal of Neuroscience | News | Comments

Researchers have discovered a new technique to enhance and maintain brain excitability that could increase sensory and pain threshold, which could be used to alleviate chronic pain in people who cannot take medication.


Genomics Researchers Unveil Road Map to Disease Origin

April 29, 2016 10:19 am | by University of Arizona Health Sciences | News | Comments

Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer's and rheumatoid arthritis - and identifying new drug targets and therapies - thanks to work by three computational biology research teams.


Scientists Turn Skin Cells into Heart, Brain Cells Using Drugs

April 29, 2016 10:15 am | by Gladstone Institutes | News | Comments

Scientists transformed skin cells into heart cells and brain cells using a combination of chemicals.


Hawaii Looks to Allow Psychologists to Prescribe Drugs

April 29, 2016 10:09 am | by Marina Starleaf Riker, Associated Press | News | Comments

State lawmakers are poised to make Hawaii one of a handful of states that allow psychologists to prescribe medication in hopes of increasing access to mental health services.


Gilead’s Profit Misses Target; HCV Drug Sales Disappoint

April 29, 2016 9:54 am | by Stephanie Guzowski, Editor | News | Comments

Gilead Sciences’s earnings missed analysts’ estimates, tumbling 17 percent in the first quarter. Lower sales of the biotech company’s blockbuster hepatitis C virus (HCV) drugs, Harvoni and Sovaldi, contributed to lower-than-expected profit.


Diagnostic Screening for Alzheimer’s Disease: Economics, Policy, and Unanswered Questions

April 28, 2016 10:01 am | by Jillian Godfrey Scaife, Principal, and Nick Simmons-Stern, Consultant, Trinity Partners | Articles | Comments

In recent years, there has been a resurgence in the number of Alzheimer’s disease (AD) clinical trials, led by major efforts from Biogen, Lilly, Genentech/Roche, and others. With the first of these novel AD therapies potentially coming to market as early as 2017/2018, there are a number of critical and as yet unanswered questions surrounding the economics and policy of AD diagnostic screening. 



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.